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The discovery that several demyelinating disorders in children may be associated with autoantibodies to astrocytes, myelin,
and/or synaptic proteins has opened the possibility of their use as diagnostic and prognostic biomarkers. The identification
of aquaporin 4 (AQP4) antibodies as specific diagnostic markers of neuromyelitis optica (NMO) led to an expansion of the
clinical spectrum of this disorder to include patients with incomplete forms or with manifestations outside of the optic
nerves and spinal cord. Recently, an international panel of experts proposed the use of the term NMO spectrum disorders
(NMOSD) to encompass all of these phenotypes. Although rare in children, the early identification of AQP4 antibodies has
important prognostic and therapeutic implications as their presence is highly predictive of relapses and accumulation of
disability. More recently, antibodies to myelin oligodendrocyte glycoprotein (MOG) have been described in children and
adults diagnosed with NMOSD and seronegative for AQP4 antibodies, as well as in children with other acquired
demyelinating disorders. For example 60 % of children with acute demyelinating encephalomyelitis (ADEM) have MOG
antibodies. Whether MOG antibodies are pathogenic or surrogate biomarkers of the disease is unclear but their
identification is important for two reasons. First, patients with a first demyelinating event who are MOG antibody
positive are unlikely to develop multiple sclerosis (MS); and second, the long-term persistence of MOG antibodies
associates with recurrent non-MS demyelinating disorders such as NMOSD, recurrent optic neuritis or transverse
myelitis, or multiphasic ADEM. Other antibodies, such as those targeting Kir 4.1 or the glycine receptor have also been
described in association with pediatric MS and other demyelinating disorders but their clinical relevance, and existence,
in the case of Kir 4.1, is still under investigation. The focus of this review will be the current data on the antibodies
mentioned above, and the recent discovery that some children have both a demyelinating disorder and autoimmune
encephalitis. The presence of antibodies against targets related to demyelinating disorders (AQP4 or MOG) and those
related to autoimmune encephalitis (e.g., N-methyl-D-aspartate receptor), supports the concurrence of two
autoimmune disorders in these patients.
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To establish the correct diagnosis and prognosis after a
first demyelinating episode in a child is challenging as,
at this age, different acquired demyelinating disorders
(ADS) can present with similar clinical features. It can
be difficult to distinguish between a monophasic illness
such as acute demyelinating encephalomyelitis (ADEM),* Correspondence: armangue@clinic.cat
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first episode of a chronic or relapsing disorder such as
multiple sclerosis (MS), neuromyelitis optica spectrum
disorders (NMOSD), or multiphasic ADEM, in which
early initiation of treatment can be crucial for prevent-
ing long-term disability [1]. Brain and spinal cord MRI
as well as the evaluation for the presence of oligoclonal
bands in the cerebrospinal fluid (CSF), are well-
characterized tools that can assist in formulating the
diagnosis of ADS [2, 3]. More recently, the discovery
that several ADS may be associated with autoanti-
bodies to astrocytes, myelin, and/or synaptic proteins
opens the possibility of utilizing these as biomarkersticle is distributed under the terms of the Creative Commons Attribution 4.0
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apies [4–6]. Here we review the current knowledge
about the antibodies associated with ADS in children.
The demographic, clinical and laboratory information
according to the antibody is summarized in Table 1.
Antibodies to astrocytes or myelin proteins
Anti-Aquaporin 4 (AQP4) antibodies and NMOSD
Neuromyelitis optica (NMO) is a rare disease. Population-
based studies estimate a prevalence of 0.52–4.4 cases/
100,000 inhabitants, with differences across studies accord-
ing to geographic and ethnic cohorts [7]. NMO is charac-
terized by recurrent inflammatory episodes that
preferentially affect the optic nerves and spinal cord [8].
The disorder predominantly affects women (90 %), and al-
though the median age at onset is 39 years, patients of all
ages can be affected including children and the elderly [9].
Overall, up to 90 % of patients have a recurrent form of the
disease, frequently with incomplete recovery between re-
lapses with incremental disability [10, 11]. Although NMO
was initially considered to be an optical-spinal form of MS,
today it is accepted as a distinct clinical-pathological entity.
The underlying pathophysiology was suspected to be B-cell
mediated due to distinctive pathologic findings showing
vasculocentric deposition of immunoglobulins (Ig), comple-
ment components within lesions, and predominance of
neutrophils and eosinophils in the inflammatory infiltrates
that are typical features of a type-2 T-helper cell immune
response [12]. The involvement of the humoral immune
system in NMO was confirmed by Lennon and colleagues
with the identification of antibodies against AQP4, a water
channel expressed predominantly in astrocyte end-feet [4,
13]. Subsequent studies demonstrated that AQP4 anti-
bodies, which belong to the IgG1 subclass, activate com-
plement and disrupt the AQP4 water channel, disturbing
water homeostasis, promoting edema and perivascular in-
flammation [14, 15]. The pathogenic role of AQP4 anti-
bodies in NMO has been demonstrated in murine models
showing NMO-like lesions after passive transfer of AQP4
antibodies from human patients [15, 16].
The identification of AQP4 antibodies led in 2006 to re-
vised NMO criteria [8]. In 2007 the term NMOSD was in-
troduced to include AQP4 seropositive patients with limited
or inaugural forms (e.g., recurrent optic neuritis or longitu-
dinally extensive transverse myelitis [LETM]), and those
with manifestations outside of the optic nerves and spinal
cord (e.g., intractable hiccups or vomiting), secondary to in-
volvement of areas also known to be rich in AQP4 such as
periventricular areas of the third and fourth ventricles, and
periaqueductal and parahippocampus grey matter [17–19].
Most recently, an International Panel proposed new diag-
nostic criteria that unified under the term NMOSD trad-
itional NMO and modern NMOSD definitions [20]. The
main reasons for the unifying term were based on theassumption that there are no biological differences between
patients diagnosed with NMO and those with NMOSD in
AQP4 seropositive patients, and that patients with limited
forms frequently develop subsequent clinical attacks consist-
ent with conventional NMO in AQP4 seropositive patients
[20]. For example, in a comparative study of patients with
AQP4 antibodies and NMO and patients with limited
forms, we found no differences in motor or visual disability
outcome, supporting the use of the term NMOSD for
patients with AQP4 antibodies [21]. However, the 2015
criteria allow the diagnosis of NMOSD in patients without
AQP4, incorporating these patients into the same group as
those with AQP4, and this is controversial. For example,
there are studies that have shown some clinical differences
between AQP4 positive and negative patients including a
lower female predominance in those without AQP4-IgG
[22, 23]. The phenotypic variability between AQP4 positive
and negative patients may be partially explained by the pres-
ence of antibodies to myelin oligodendrocyte glycoprotein
(MOG) in a subgroup of AQP4 seronegative patients, as pa-
tients with MOG antibodies may develop a clinical picture
indistinguishable from NMOSD but with better outcome
[22, 24]. This likely represents a different immunopatho-
genic mechanism that would not be clear using descriptive
clinical terms, such as NMO or NMOSD [24]. Therefore,
some authors suggest replacing these terms by a pathogeni-
cally descriptive name such as “autoimmune channelopathy
due to AQP4 antibodies” to exclude patients without AQP4
antibodies such as patients with MOG antibodies, which
probably underly a different biologic disease. Autoimmune
channelopathy due to AQP4 antibodies would also encom-
pass other AQP4 related non-CNS disorders such as the re-
cently described disorders with hyperCKemia and/or
skeletal muscle involvement [25, 26]. This systemic involve-
ment is not surprising as AQP4 channels are also expressed
in normal muscles [27].
Characteristics of NMOSD with AQP4 antibodies in children
It is estimated that almost 70 % of adults with NMOSD have
AQP4 antibodies [28]. In contrast these antibodies are rare
in the pediatric population [29]. Among different prospective
case series, up to 5 % of children with demyelinating diseases
harbor these antibodies [30, 31]. However, a study evaluating
specific clinical phenotypes found that almost half of children
with classic NMO features harbored AQP4 antibodies [30].
The presence of these antibodies has important clin-
ical and prognostic implications. For example, seroposi-
tivity for AQP4 antibodies in a first inflammatory
episode is highly predictive for relapses, and relapses
are associated with long-term disability in both children
and adults [9, 29, 30]. In a series of 48 children with
NMOSD and AQP4 antibodies, 54 % had visual impair-
ment (27 % bilateral visual acuity ≤ 20/200), 54 % had
residual weakness (29 % with paraparesis), and 12 %
Table 1 Antibodies in acquired demyelinating disorders in children
AQP4 antibodies MOG antibodies Kir 4.1 antibodies NMDAR antibodies Glycine R antibodies
Syndrome NMOSD with predominant
involvement of optic nerve and
spinal cord. Additional
manifestations are related to
involvement of other areas rich in
AQP4, such as area postrema
(hiccups or nausea and vomiting),
hypothalamus, surrounding the third
ventricle (symptomatic narcolepsy




Described in all types of ADS;
predominant in ADEM, followed by
in order of frequency in NMOSD,
optic neuritis, and extensive myelitis.
Rarely seen and at lower titers in
multiple sclerosis
Described in association with
adults (47%) and children (57%)
with multiple sclerosis; results
have not been reproduced by
other investigators who showed
much lower association (< 1–24%)





autonomic instability, and coma.
Stiff person syndrome in




and myoclonus, and rarely in
several types of demyelinating
syndromes: optic neuritis,
multiple sclerosis
Rarely, overlap with clinical and/or
radiological ADS, frequently with
concomitant MOG and/or AQP4
antibodies: presentation can be
sequential or simultaneous
Pathogenesis Activate complement and disrupt
the AQP4 water channel located
at astrocyte end-feet
Whether MOG antibodies are
pathogenic or serve as surrogate
biomarkers of the disease is currently
unclear
Clinical significance and existence
remains a matter of debate
In vitro and in vivo models show
decrease levels of NMDAR
Lack of clinical syndrome
specificity and the fact these
antibodies are frequently
found in patients with ADS
concurrent with other more
pathogenically relevant
antibodies such as MOG and/
or AQP4, suggests nonspecific
immune activation
Age, Sex More common in adults (median
age 39 years), but the disorder
affects patients of all ages with a
female predominance
Mostly in children with no sex
predominance
No differences were found
compared to MS patients without
these antibodies
Predominant in children and young
adults. Sex and tumor association
(teratoma) is agedependent, but no
tumor association has been
described in patients with
overlapping ADS
Predominance depends on
the syndrome in which the
antibodies are analyzed; in
ADS, there are no differences
compared to patients without
these antibodies.
MRI Spinal cord lesions extending over
≥ 3 contiguous segments (Fig. 1a, d);
area postrema lesions; periependymal
brainstem lesions; chiasmatic
involvement; and diencephalic lesions.
In children, extensive brain lesions
similar to that found in ADEM
Typically large, hazy, bilateral lesions
in patients with ADEM and MOG
antibodies (Fig. 1b, c). Patients with
NMOSD can show similar MRI
features to those found in patients
with AQP4 antibodies
No specific reported data
comparing MRI features of
patients with or without these
antibodies
Normal or T2/FLAIR nonspecific
findings in anti-NMDAR encephalitis
but can show demyelinating features
with overlapping ADS
Depends on the associated
clinical syndrome; in ADS very
few reported patients but
appears to be no differences
compared to patients without
these antibodies
Relapses The presence of AQP4 antibodies in
NMOSD patients is associated with
increased risk of recurrences and
increased long-term disability
compared to patients without these
antibodies. AQP4 antibody titers
persist long term.
Frequently monophasic course with
good recovery (antibody titers often
become negative) (Fig. 1e, f). In some
cases, associated with non-MS multi-
phasic disease; there can be long-
term persistence of antibodies.
NMOSD patients with MOG anti-
bodies have better prognosis com-
pared to patients with AQP4
antibodies
No differences were found
compared to MS patients without
these antibodies. One study
found higher titers during
relapse versus remission in
patients with MS
15–25% of patients of anti-NMDAR
encephalitis may develop recurrences.
Prevalence of NMDAR encephalitis
or ADS relapses is unknown in
overlapping syndromes
Depends on the associated
clinical syndrome; in ADS very
few reported patients but
appears to be no differences




















Table 1 Antibodies in acquired demyelinating disorders in children (Continued)
Laboratory
Test
Serum CBA (microscopy or flow
cytometry-based detection) had
a sensitivity of 76.7% in a pooled
analysis and 0.1% falsepositive rate
in a multiple sclerosis clinic cohort.
Indirect immunofluorescence assays
and ELISAs have lower sensitivity
(63–64% each) and occasionally
yield false-positive results (0.5–1.3%
for ELISA), especially when the
titer is low
Serum CBA (positivity threshold is
considered up to 1/160). Some
authors use human IgG1 subclass
as a secondary antibody to avoid
false positive results. ELISA was
used in the past with controversial
results, and this technique is not
recommended
ELISA Fixed CBA and immunochemistry.
Lower sensitivity in serum compared
with CSF (85 vs 100%), and false
positive results are possible when
only serum is tested. Confirmation
by two different techniques is
preferred when the clinical
syndrome does not fit with the lab
result or when only serum
is tested
Live CBA (positivity threshold
is considered up to 1/80)
ADEM acute demyelinating encephalomyelitis; ADS acquired demyelinating disorders; AQP4 aquaporin 4; CBA cell-based assay; CSF cerebrospinal fluid; FLAIR fluid-attenuated inversion recovery; Glycine R glycine
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12 months) [29].
Another example of the importance of identifying these
antibodies is that in children AQP4 antibody associated
disorders can present with encephalopathy mimicking
ADEM or with lesions on brain MRI that simulate MS [1,
29, 32, 33]. Moreover, CSF abnormalities in pediatric MS
may mimic those ordinarily considered suggestive of
NMOSD [29, 30, 33]. Additionally, while an adult with
LETM is commonly suspected to have AQP4-NMOSD, in
children, this diagnosis is often not suspected as LETM
also occurs with ADEM and MS [1]. Other differences be-
tween children and adults with NMOSD appears to be a
lower female preponderance in children (3:1 female:male
ratio compared with up to 9:1 for adults) [33]; and that a
greater proportion of children may have monophasic dis-
ease [30, 33]. Aside from these caveats, the currently pro-
posed diagnostic criteria for NMOSD are considered
appropriate for pediatric patients [20].
Misdiagnosing NMOSD for MS in children can be
deleterious as standard treatments for MS such as beta
interferon, fingolimod or natalizumab can result in
worsening of NMOSD [34, 35]. In contrast, treatment
strategies that selectively target the cellular and soluble
components of the humoral immune response in
NMOSD, such as plasma exchange and B-cell depletionFig. 1 MRI in children with demyelinating syndromes associated with MOG
girl with NMOSD and AQP4 antibodies. The sagittal MRI of the spinal cord
brain axial T2-sequence shown in (d) is normal. (b, c, e, f): Coronal FLAI
and MOG antibodies showing bilateral widespread subcortical lesions (
resolution of the lesions (e, f)(e.g., rituximab), have been shown to be effective in the
prevention of NMOSD relapses [36].
Based in the growing knowledge about the pathophysi-
ology of NMOSD with AQP4 antibodies there are many
studies examining new targeted therapies that will hope-
fully result in better outcomes for these patients. Examples
include eculizumab, which acts to inhibit complement ac-
tivation; tocilizumab, which acts by blocking the cytokine
IL6 receptor; antibodies directed against the CD19 mol-
ecule expressed by B cells; and the monoclonal antibody
aquaporimab, which is designed to block the interaction
between human IgG and AQP4 [37–40].
In summary, for the reasons noted above although
the prevalence of AQP4 antibodies is low in the
pediatric population, determination of these anti-
bodies should be considered in any child with a first
demyelinating episode involving one or more areas
rich in AQP4.
MOG antibody-associated disorders in children
Antibodies against MOG have been associated with
several types of acquired demyelinating disorders in
children [5]. The specificity of MOG antibodies for
demyelinating disorders was questioned in the past
due to conflicting results from studies using ELISA
or western blot, techniques that measure antibodyor AQP4 antibodies. (a, d): Brain and spinal cord MRI of a 13-year old
shows hyperintensity involving more than 3 segments (a) whereas the
R-sequences of an 8-year old girl with an initial episode of ADEM
b, c). Seven months after the attack there has been complete
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CBA (cell-based assays), in which antibody binding to
conformational epitopes is assessed, has shown that
MOG antibodies are able to identify patients with ac-
quired demyelinating disorders [5]. These findings
demonstrate the value of a multi-technique labora-
tory approach in autoantibody research and valid-
ation. Although there is some in vitro and in vivo
data suggesting a pathogenic role of MOG antibodies,
[41] there are no studies demonstrating that passive
transfer of these antibodies leads to clinical disease,
as has been demonstrated in animal models of AQP4
autoimmunity [16].
Whether MOG antibodies are pathogenic or repre-
sent surrogate biomarkers of the disease is currently
unclear. However, preliminary data support that the de-
termination of these antibodies is important [5]. In chil-
dren, ADEM is the clinical syndrome that most
frequently associates with MOG antibodies (present in
up to 60 % of cases) [5]. A recent study compared 19
children with ADEM with MOG antibodies to 14 pa-
tients with ADEM without these antibodies [42]. There
were no differences in in age at presentation, gender,
symptoms, initial disease severity, or the presence of
oligoclonal bands between children with or without
MOG antibodies. However, children with ADEM and
MOG antibodies more often had MRI findings charac-
terized by large, hazy, bilateral lesions in the brain and
an increased frequency of LETM. Children with MOG
also had more favorable outcomes compared to those
lacking these antibodies [42].
Several studies have shown that MOG antibody titers
decline and become negative over time in patients with
monophasic ADEM [43, 44]. A few initial reports postu-
lated that the long-term persistence of MOG antibodies
in a child could be predictive of the eventual develop-
ment of pediatric MS [43]. Recent studies demonstrate
that in fact, MOG antibodies are rarely found in
pediatric MS and their presence supports a diagnosis
other than MS [45]. For example, in a recent prospective
series of 65 children with a first demyelinating attack,
only 2/23 (9 %) with MOG antibodies compared with
16/42 (38 %) without these antibodies were diagnosed
with MS after one year of follow-up, supporting the
positive predictive value of MOG antibodies for a non-
MS disease course [45]. However as these studies are
based on short follow-up periods, longer time is needed
to exclude eventual conversion to MS.
In contrast, there are several studies in children that
support an association of the long-term persistence of
MOG antibodies with recurrent non-MS demyelinating
disorders such as NMOSD, recurrent optic neuritis,
transverse myelitis or multi-phasic ADEM (Armangue
personal observation) [41, 46–48]. Interestingly, theseantibodies have also been described in a subgroup of
ADS patients who initially presented with monophasic
ADEM that fulfilled all clinical and neuroradiological
criteria who subsequently develop one or more episodes
of optic neuritis (ON) without further neuroradiological
changes suggestive of demyelination. This clinical sce-
nario named by some authors as ADEM-ON, [49] does
not fall into any of the current diagnostic categories of
ADS in children proposed by the International Pediatric
MS Study Group, [1] but these patients who are at risk
for subsequent clinical events could have NMOSD,
chronic relapsing inflammatory optic neuropathy or MS,
require close follow-up.
After ADEM, the most frequent syndrome associated
with MOG antibodies in children is NMOSD (20 % of
patients) [5, 50]. Compared to NMOSD with or without
AQP4 antibodies, NMOSD with MOG antibodies has
distinctive clinical and prognostic features [22, 51, 52].
Patients with NMOSD and MOG antibodies are slightly
more likely to be male in contrast to the greater female
predominance in cases associated with AQP4. Patients
with NMOSD with MOG are more likely to have optic
nerve than spinal cord involvement as well as more fre-
quent involvement of the conus and the basal ganglia on
MRI, in contrast to what is seen in NMOSD AQP4 pa-
tients [22, 51, 52].
In adults, the presence of MOG is predictive of better
outcome in NMOSD compared to NMOSD with AQP4
antibodie [22, 51, 52]. In a study in which we evaluated
174 adults patients with NMOSD, ON or transverse
myelitis, patients with MOG antibodies more frequently
had a monophasic course (41 % vs 7 %) and better prog-
nosis (median EDSS score 1.5 vs 4.0) compared to pa-
tients with AQP4 antibodies, despite having similar
severity scores at disease onset [22]. Whether these re-
sults can be extrapolated to the pediatric population is
unknown and requires further study.
Pathological studies are not available from patients
with NMOSD and MOG antibodies. Studies of CSF from
these patients show increased levels of myelin basic pro-
tein and undetectable levels of glial fibrillary acidic pro-
tein (GFAP). This is in contrast to the CSF findings in
patients with NMOSD and AQP4 antibodies that show
low levels of myelin basic protein and elevated GFAP
[53]. This supports the hypothesis that MOG associated
disease is due to demyelinating pathology rather than an
astrocytopathy, and this could explain the clinical differ-
ences between NMOSD patients with AQP4 and those
with MOG antibodies.
Kir 4.1 IgG antibodies
In 2012, the KIR4.1 (also known as KCNJ10), a glial in-
wardly rectifying potassium channel expressed on oligo-
dendrocytes and astrocytes, was proposed as a putative
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KIR4.1-channel-specific IgG in serum of 47 % (189/397)
of adult MS patients and < 1 % of patients with other
neurological disorders [54]. In a subsequent study these
antibodies were also reported in the serum of 57 % (24/
47) of children with acquired demyelinating syndromes
[55]. However this high prevalence of anti-KIR4.1 anti-
bodies in patients with MS has not been corroborated
by other groups. Using similar methods, other studies in
MS patients have shown much lower frequencies of
these antibodies (from < 1 to 26 %), and the antibodies
were also present to the same degree in normal subjects
and other disease controls such as NMOSD patients
[56–58]. Moreover, a recent study using a multi-
technique approach did not detect KIR4.1-specific IgG
in serum or CSF from patients with MS. No KIR4.1 loss
from glia was seen in MS lesions and false positive re-
sults were demonstrated on ELISA [56]. The discrepan-
cies between the results of these studies are difficult to
explain, [59] but different analytical approaches might,
in part, explain the contradictory findings. The potential
relationship between KIR4.1 antibodies in MS deserves
further investigation [59].
Antibodies to the Neuronal Cell Surface
Overlap between demyelinating syndromes and
autoimmune encephalitis
The differential diagnosis of encephalopathy in children
includes ADEM, NMOSD and autoimmune encephalitis
associated with antibodies to neuronal cell-surface or
synaptic proteins such as N-methyl-D-aspartate receptor
(NMDAR) and others [60]. The clinical syndrome of
anti-NMDAR encephalitis is highly predictable in adults
and teenagers and is characterized by the onset of psy-
chiatric and behavioral problems that progress to de-
creased level of consciousness, seizures, dyskinesias,
choreathetoid movements or postures, and breathing or
autonomic instability [61, 62]. In young children, the
syndrome is similar, but children more frequently
present with seizures or abnormal movements. More-
over, behavioral changes are often misdiagnosed as they
may include new onset temper tantrums or agitation,
which are frequent and non-specific at this age [62, 63].
In contrast to what is found in ADEM or in other ADS,
in anti-NMDAR encephalitis brain MRI is typically nor-
mal or may show non-specific FLAIR/T2 changes, some-
times with transient cortical-meningeal enhancement
[64]. A new challenge that has emerged is the finding
that patients may have both demyelinating disease and
autoimmune encephalitis [6]. The presence of two im-
mune disorders in these patients is supported by the
finding of antibodies against targets related to demyelin-
ating disorders (AQP4 or MOG) and those related to
autoimmune encephalitis (e.g., NMDAR) [6]. In thesepatients, the two disorders may occur sequentially as
independent episodes separated by weeks to years or
may occur simultaneously [6, 65]. The latter is the most
diagnostically challenging. The presence of clinical or
radiologic features characteristic of demyelination in a
patient with autoimmune encephalitis and neuronal
cell-surface antibodies should prompt testing for MOG
and/or AQP4 antibodies. Similarly, patients with de-
myelinating disorders who develop unusual symptoms
such as dyskinesias, refractory seizures, or prominent
psychiatric symptoms should be tested for cell-surface
antibodies (preferably in CSF, see Table 1) [6, 66].
While the identification of different antibodies can con-
firm the dual diagnoses, awareness that these disorders
may overlap is the first step to establishing the correct
diagnoses.
Glycine antibodies and demyelinating syndromes
Antibodies to glycine receptor (GlyR) were initially de-
tected in serum and CSF of patients with progressive en-
cephalomyelitis with rigidity and myoclonus (PERM),
[67] but have since been reported in other subgroups of
patients including patients with stiff-person syndrome,
cerebellar ataxia and several types of demyelinating dis-
orders in children and adults (e.g., optic neuritis and
MS) [31, 68, 69].
This lack of syndrome specificity and the fact these
antibodies are frequently found in patients with ADS
concurrent with other more pathogenically relevant
antibodies such as MOG and/or AQP4, [69] suggests
that these antibodies may be non-specific markers of
autoimmunity.
Conclusions
The differential diagnoses of a child presenting with a
first episode of demyelination is wide and includes dis-
eases with different pathogenic mechanisms. This can
delay diagnosis and initiation of appropriate therapies,
which may affect disease course and outcome.
The discovery of AQP4 antibodies allows for early iden-
tification of patients with similar pathophysiology and
prognosis, thereby supporting the use of specifically di-
rected therapeutic interventions. Antibodies to MOG have
recently been postulated to be markers of non-MS demye-
linating diseases in children and may identify patients with
high risk of developing relapses. The identification of
AQP4 or MOG antibodies concurrent with NMDAR anti-
bodies in patients with autoimmune encephalitis has
uncovered the fact that some patients can have both auto-
immune encephalitis and a demyelinating disorder. Fur-
ther investigation will clarify the role of the antibodies
discussed above in these diseases and will likely lead to
the discovery of additional antibody biomarkers that may
facilitate diagnosis and serve as prognostic tools.
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